von Marcel Wiesweg ; Ali Alaffas ; Anna Rasokat ; Felix Carl Saalfeld ; Maximilian Rost ; Christin Assmann ; Franziska Herster ; Moritz Hilbrandt ; Frank Griesinger ; Anna Kron ; Julia Roeper ; Franziska Glanemann ; Cornelia Kropf-Sanchen ; Martin Reck ; Jonas Kulhavy ; Albrecht Stenzinger ; Jürgen Wolf ; Martin Sebastian ; Martin Schuler ; Martin Wermke ; Nikolaj Frost ; Hans-Georg Kopp ; Petros Christopoulos ; Matthias Scheffler
Online verfügbar 8 May 2025, Version des Artikels 4 September 2025 ; Gesehen am 04.02.2026
BRAF; Immunotherapy; NSCLC; PD-L1; Sex
Background - Targeted treatment of patients with metastatic BRAF-V600-mutated NSCLC using BRAF/MEK-inhibitors is effective but limited by acquired resistance. Patients with BRAF-mutant NSCLC may derive long-lasting benefit from immune checkpoint inhibition with programmed death-1/programmed death-ligand 1 (PD-L1) antibodies (immuno-oncology [IO]). Although IO is the preferred first-line therapy in BRAF-mutated melanoma, the optimal treatment sequence in BRAF-mutated NSCLC is not defined. - Methods - This retrospective study investigated the clinical outcome of patients with metastatic BRAF-V600-mutated NSCLC diagnosed in the German national Network Genomic Medicine Lung Cancer. - Results - We identified 205 patients with BRAF-V600-mutated NSCLC; 175 patients received first-line therapy with dabrafenib/trametinib (DAB/TRM, 65.1%), IO alone (19.4%), or chemotherapy-IO (15.4%). Overall survival (OS) and time-to-treatment failure of first-line therapy was identical for patients receiving first-line DAB/TRM (median OS 28.0 months) or chemo/IO (27.8 months, hazard ratio [HR] 1.1, p = 0.68). Female patients had superior OS (HR 0.65, p = 0.049, confirmed in multivariate model), which was mainly driven by superior OS of female to that of male patients receiving first-line DAB/TRM (OS HR 0.53, p = 0.015). There was no sex difference in survival of patients receiving IO-based first-line treatment (OS HR 1.02). Surprisingly, high PD-L1 status (tumor proportion score ≥50%) was associated with shortened time-to-treatment failure in first-line treatment (HR 1.83, p = 0.002, confirmed in multivariate models adjusting for sex; OS with nonsignificant trend, HR 1.4), regardless of whether the first-line regimen was IO-based or targeted therapy. - Conclusions - Targeted or IO-based first-line treatment of BRAF-V600-mutated NSCLC has similar survival outcomes. Sex and PD-L1 status may support decision-making at the individual patient level.
Journal of thoracic oncology Amsterdam : Elsevier, 2006 20(2025), 9 vom: Sept., Seite 1328-1335 Online-Ressource
von Esin Aysel Kandemir ; Julia Roeper ; Heiner Zimmermann ; Lena Ansmann ; Petra Hülper ; Maximilian Bockhorn ; Claus-Henning Köhne ; Frank Griesinger
von Rajiv Shah ; Eva L. Buchmeier ; Hans-Georg Kopp ; Daniel C. Christoph ; Frank Griesinger ; Martin Reck ; Petra Hoffknecht ; Jonas Kuon ; Nikolaj Frost ; Christian Grohé ; Martin Faehling ; Jingting Luan ; Julia Roeper ; Paolo Chesi ; Miriam Blasi ; Martin Kimmich ; Till Olchers ; Helge Bischoff ; Laura Valentina Klotz ; Inn Chung ; Petros Christopoulos ; Michael Thomas
Background - Despite the approval of nivolumab/ipilimumab, the prognosis of patients with pleural mesothelioma (PM) remains poor. Although this combination has shown improved survival in the landmark CheckMate (CM)-743 trial, evidence from real-world settings remains limited. - Methods - In this retrospective, multicenter study, the outcome and safety data for 135 consecutive patients with first-line nivolumab/ipilimumab were evaluated among 1,575 adult patients with PM from 12 German cancer centers. Radiologic response and progression were analyzed according to the revised modified RECIST criteria. - Results - The median overall survival (OS) was 13.1 months for the unselected real-world cohort, and 15.5 months for CM-743-eligible patients (16.7 months for the non-epithelioid and 10 months for the epithelioid subtypes). Patients who experienced partial responses to nivolumab/ipilimumab had significantly longer survival than those without (24 months vs. 10.3 months; p = 0.00026). 37 % of patients experienced immune-related adverse events (irAEs), among whom 58 % had grade 3/4 toxicity. IrAEs of any grade were associated with longer survival (17.3 months vs. 11.7 months for patients without irAEs; p = 0.022). Furthermore, grade 1/2 irAEs were associated with even better outcomes when compared to grade 3/4 toxicities (22.7 months vs. 16.7 months median OS) and absence of toxicity (p < 0.0167 for trend). - Conclusions - Overall survival with first-line nivolumab/ipilimumab in the real-world setting is comparable to the CM-743 results among trial-eligible patients, especially with non-epithelioid tumors, but shorter for the unselected cohort. IrAEs, in particular those of low-grade, were associated with better outcomes. In the absence of predictive biomarkers and with few therapeutic options available, both dual checkpoint blockade and platinum-pemetrexed chemotherapy remain viable first-line regimens.
Lung cancer Amsterdam [u.a.] : Elsevier, 1985 207(2025) vom: Sept., Artikel-ID 108702, Seite 1-10 Online-Ressource
Brustkrebs ist unter Frauen weiterhin sowohl in Niedersachsen als auch in ganz Deutschland die häufigste Krebserkrankung. Die Betreuung der Patientinnen und Patienten kann sowohl in zertifizierten Brustzentren als auch in externen onkologischen Einrichtungen erfolgen. Im Rahmen des zertifizierten Brustkrebszentrums des Pius Hospitals wurde für die in dieser Studie betrachteten Patientinnen in einer interdisziplinären Tumorkonferenz ein individueller Therapieplan erstellt, der die aktuellen Empfehlungen der fachspezifischen Leitlinie beachtet. Die vorliegende Arbeit untersucht die Adhärenz der Tumorboardempfehlungen sowie dessen Einfluss auf das Gesamtüberleben. Zusätzlich werden mögliche Einflussfaktoren auf das Überleben ausgewertet, um für zukünftige Therapiekonzepte bestmöglich auf die Lebensumstände der Patientinnen eingehen zu können. Die retrospektiv durchgeführte Studie überprüft die Einhaltung der in den interdisziplinären Tumorkonferenzen empfohlenen Therapiekonzepte von Mammakarzinompatientinnen im Pius Hospital Oldenburg im Zeitraum von Januar 2014 bis Dezember 2018. Eingeschlossen wurden 1122 Patientinnen, die primär im Pius Hospital Oldenburg operiert wurden. Die am Brustzentrum des Pius Hospital Oldenburg betreuten Patientinnen weisen in größerem Maße eine Einhaltung der Tumorkonferenzbeschlüsse und ein längeres Überleben im Vergleich zu extern betreuten Patientinnen auf. Zusätzlich haben die Parameter verheiratet/verpartnert, ein CCI ≤ 2, ein positiver Hormonrezeptorstatus, die UICC-Stadien 0-II, das Fehlen von Fernmetastasen, eine Weiterbehandlung am zertifizierten Brustzentrum sowie die vollständige Adhärenz einen signifikanten Einfluss auf das Überleben.
Breast cancer still is the most diagnosed cancer entity in Lower Saxony and all over Germany. Patients can be cared for in certified breast cancer centers as well as in external oncological institutions. Breast cancer patients of the certified breast cancer center at Pius Hospital have been given individual treatment plans, which have been developed by an interdisciplinary tumor conference. This paper examines adherence to tumor conference decisions and the impact on overall survival. Furthermore, possible impact factors on survival are evaluated to respond to living circumstances of the patients regarding future treatment plans. This paper is a retrospective study to survey the adherence of breast cancer patients to recommended treatment plans of interdisciplinary tumor conferences in the Pius Hospital Oldenburg from January 2014 to December 2018. 1122 patients, who had primary surgery at Pius Hospital Oldenburg, have been included. Patients being treated at breast center Pius Hospital Oldenburg show a higher adherence to tumor conference decisions and a longer survival compared to patients, who were cared for externally. Furthermore, being married/partnered, a CCI ≤ 2, a positive hormone receptor status, UICC stages 0-II, no metastases, further treatment at the certified breast cancer center, and complete adherence have significant impact on survival.
